CytomX Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $12,667 | $38,052 |
| Short-term investments | 124,385 | 62,571 |
| Accounts receivable | 2,013 | 3,103 |
| Prepaid expenses and other current assets | 4,856 | 3,579 |
| Total current assets | 143,921 | 107,305 |
| Property and equipment, net | 1,304 | 2,467 |
| Intangible assets, net | 438 | 583 |
| Goodwill | 949 | 949 |
| Restricted cash | 1,527 | 1,027 |
| Operating lease right-of-use asset | 3,396 | 8,136 |
| Other assets | 31 | 66 |
| Total assets | $151,566 | $120,533 |
| Liabilities and Stockholders' Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable | $1,301 | $1,088 |
| Accrued liabilities | 14,197 | 12,338 |
| Operating lease liabilities - short term | 4,240 | 5,145 |
| Deferred revenue, current portion | 26,877 | 67,201 |
| Total current liabilities | 46,615 | 85,772 |
| Deferred revenue, net of current portion | 1,590 | 26,862 |
| Operating lease liabilities - long term | — | 4,240 |
| Other long-term liabilities | 4,353 | 4,115 |
| Total liabilities | 52,558 | 120,989 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity (deficit) | ||
| Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding | — | — |
| Common stock, $0.00001 par value; 300,000,000 and 150,000,000 shares authorized, and 170,186,365 and 80,099,889 shares issued and outstanding at December 31, 2025 and 2024, respectively | 2 | 1 |
| Additional paid-in capital | 810,844 | 691,095 |
| Accumulated other comprehensive income | 111 | 27 |
| Accumulated deficit | (711,949) | (691,579) |
| Total stockholders' equity (deficit) | 99,008 | (456) |
| Total liabilities and stockholders' equity (deficit) | $151,566 | $120,533 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.